Last checked at 28 Sep 2010 10:18
| For Immediate Release | 28 September 2010 |
ImmuPharma PLC
Notification of Interim Results
ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, is scheduled to announce its Interim Results for the six months ended 30 June 2010 on Thursday 30th September 2010.
For further information please contact:
| ImmuPharma PLC: |
|
| Dimitri Dimitriou, Chief Executive Officer | +44 20 7152 4080 |
| Dr Robert Zimmer, President & Chief Scientific Officer | + 33 389 32 76 50 |
| Richard Warr, Chairman | +44 20 7152 4080 |
|
|
|
| Buchanan Communications | + 44 20 7466 5000 |
| Lisa Baderoon |
|
| Mark Court |
|
| George Prassas |
|
| Panmure Gordon & Co (NOMAD & Broker) | + 44 20 7459 3600 | |
| Andrew Burnett |
| |
| Rakesh Sharma |
| |
|
|
|
|
| Execution Noble (Joint Broker) |
|
|
| James Bromhead | + 44 20 7456 9191 |
|
| Richard Crawley |
|
|
Notes to Editors:
About ImmuPharma
ImmuPharma PLC is a drug discovery and development company headquartered in London, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It has research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases characterised by:
·; blockbuster potential in niche markets
·; low promotional costs in few specialised physicians and centres and
·; lower risk of drug development and lower development costs
ImmuPharma is a currently developing drug candidates for three different medical conditions, each of which would represent a significant breakthrough in its field. The furthest advanced drug candidate targets Lupus, a disease for which there is currently no cure or specific treatment. The other two address moderate to severe pain (such as that experienced by cancer sufferers and post-operative patients), and MRSA and similar severe hospital-acquired resistant infections.
All three have significant sales potential as well as low marketing costs and a relatively low risk of development failure. One or more have the potential to be fast-tracked by the US Food and Drug Administration according to "Guidance for Industry: Fast Track Drug Development Programs - Designation, Development and Application Review" issued July 2004 and could therefore obtain their market authorization by 2010.
Key to the potential success of ImmuPharma is its unique collaborative agreement with Centre National de la Recherche Scientifique, France's scientific research institution. This agreement grants ImmuPharma worldwide exclusive rights to exploit certain key discoveries.
In addition to its three leading drug candidates, ImmuPharma has a drug development pipeline using its rights to a virtual chemical library of hundreds of thousands of molecules as well as an innovative technology for converting peptides to drug candidates.
ImmuPharma has the option to commercialise its assets itself or to license them to other pharmaceutical companies at an earlier stage.